ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) completed the sale of its subsidiary, Shanghai Zhangtou Yaoxin Technology Development, to Shanghai Zhangjiang Group, according to a Friday Hong Kong bourse filing.
The biopharmaceutical firm has already received the first two payment installments of 66.2 million yuan and is set to receive the last one within 10 business days from the date on which the adjusted amount is determined.
The disposal was first announced on Dec. 30, 2024, with ImmuneOnco agreeing to sell the subsidiary for up to 98.2 million yuan.
Shanghai Zhangtou Yaoxin Technology Development was formed to hold an industrial property-holding company in Shanghai.
Shares of the company were down nearly 15% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。